不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CD20 阳性 T 和 NK 细胞淋巴瘤的发病机制、诊断、治疗与预后：综述
英文原题：Pathogenesis, Diagnosis, Treatment, and Prognosis of CD20-Positive T and NK Cell Lymphoma: A Review.
查看英文原题
Pathogenesis, Diagnosis, Treatment, and Prognosis of CD20-Positive T and NK Cell Lymphoma: A Review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
异常表达CD20的T细胞和NK细胞淋巴瘤主要见于亚洲人群。由于CD20表达存在差异，其来源难以一概而论，CD20的作用也因此存在争议。本综述概述三类细胞中CD20的定位和功能。在NK/T细胞淋巴瘤（NKTCL）中，研究发现CD20仅见于B细胞，这些细胞呈成熟活化表型，且病程惰性。然而，在T细胞淋巴瘤（TCL）中，T细胞和NK细胞上CD20抗原表达不一，并与肿瘤转化及利妥昔单抗疗效相关。我们强调CD20表达具有阶段特异性，并进一步对CD20抗原归属进行分类，以帮助理解肿瘤不同发展阶段结局的差异及CD20的作用。
展开英文摘要原文
T and NK cell lymphoma with abnormal CD20 expression is a condition that primarily seen in Asians. Due to the variable expression of CD20, it is difficult to generalize its origin, leading to controversial conclusions about the role of CD20. In this review, we provide an overview of CD20 localization and function in three cell types. In NK/T-cell lymphoma (NKTCL), CD20 was discovered to be confined to B cells, presenting a mature active phenotype and having an inert course.
However, in T-cell lymphoma (TCL), variable expression of CD20 antigen on T cells and NK cells correlates with tumor transformation and rituximab efficacy.
We highlight the fact that CD20 expression is stage-specific and further classify CD20 antigen assignment, which contributes to understanding the variety of outcome and the function of CD20 during various phases of tumor development.
论文信息
- 作者
- Liu Y、Li B、Chen X、Xiong H、Huang C
- 第一作者单位
- Affiliated Hospital of Southwest Medical University.
- 通讯作者单位
- Stem Cell Immunity and Regeneration Key Laboratory of Luzhou, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China; Department of Hematology, The Affiliated Hospital, Southwest Medical University, Luzhou, China.China
- 文献类型
- 综述
- 期刊
- Critical reviews in immunology2025
- 原文标识
- PubMed 40460386 · DOI 10.1615/CritRevImmunol.2025051500